The COOL-AF Phase 2 Registry: COhort of Antithrombotic Use and Clinical Outcomes in Atrial Fibrillation Patients.

ABSTRACT:

Background

Atrial fibrillation (AF) is a common condition leading to an increased risk of death and complications such as stroke. Even though direct oral anticoagulants (DOACs) can reduce the risk of ICH, the rate of DOAC use remains low in many Asian countries because of cost concerns.

Objectives

The purpose of this protocol paper of the COOL-AF (COhort of antithrOmbotic use and cLinical outcomes in patients with Atrial Fibrillation) Phase 2 registry is to determine the rate of clinical outcome, changes in antithrombotic patterns, and their impact on clinical outcomes, and to develop a prediction model for clinical outcomes.

Methods

The COOL-AF Phase 2 study is a prospective observational multicenter study of patients with known or newly diagnosed nonvalvular AF in T

SUBMITTER: Krittayaphong R 

PROVIDER: S-EPMC11782006 | biostudies-literature | 2025 Jan

REPOSITORIES: biostudies-literature